Valuation: United Therapeutics Corporation

Market Cap 25.18B 22.82B 21.1B 19.04B 35.88B 2,374B 37.15B 254B 101B 1,268B 94.48B 92.48B 4,025B P/E 2026 *
23.7x
P/E 2027 * 18.8x
Enterprise Value 22.39B 20.29B 18.76B 16.93B 31.9B 2,111B 33.03B 225B 89.38B 1,128B 84.01B 82.23B 3,579B EV / Sales 2026 *
6.87x
EV / Sales 2027 * 5.91x
Free-Float
52.87%
Yield 2026 *
-
Yield 2027 * -
1 day-0.36%
1 week+5.19%
Current month-1.26%
1 month+9.17%
3 months+18.30%
6 months+3.97%
Current year+21.33%
1 week 577.26
Extreme 577.26
598.84
1 month 534.61
Extreme 534.61
614.23
Current year 455.63
Extreme 455.63
614.23
1 year 455.63
Extreme 455.63
614.23
3 years 208.62
Extreme 208.6249
614.23
5 years 158.38
Extreme 158.38
614.23
10 years 74.31
Extreme 74.31
614.23
Manager TitleAgeSince
Chief Executive Officer 71 25/06/1996
President 54 25/06/2016
Director of Finance/CFO 58 12/03/2015
Director TitleAgeSince
Director/Board Member 78 31/12/2001
Chairman 71 25/06/1996
Director/Board Member 92 31/12/2001
Date Insider Type Main position Quantity % Market Cap. Importance
05/11/26 Sell

Chief Executive Officer

-1,960 0.0046%
05/11/26 Exercice

Chief Executive Officer

26,540 0.0619%
05/11/26 Exercice

General Counsel

24,900 0.0581%
Change 5-day change 1-year change 3-year change Capi.($)
-0.36%+5.19%+26.75%+157.86% 25.18B
+1.14%+6.61%+40.79%+145.27% 1,286B
+0.79%+3.45%+45.84%+92.04% 688B
+0.20%+1.28%+26.97%+114.41% 521B
+0.83%+1.67%+41.99%+72.18% 386B
+0.55%+0.70%+59.02%+45.79% 364B
+1.02%+1.47%+28.02%+62.71% 302B
+0.34%-0.31%+3.16%+37.93% 287B
-0.30%+1.14%+38.29%+70.56% 252B
+0.08%+0.71%+34.44%+123.99% 208B
Average +0.57%+2.39%+34.53%+92.27% 432B
Weighted average by Cap. +0.79%+3.27%+37.65%+99.94%

Financials

2026 *2027 *
Net sales 3.26B 2.95B 2.73B 2.46B 4.64B 307B 4.81B 32.81B 13.01B 164B 12.23B 11.97B 521B 3.6B 3.27B 3.02B 2.73B 5.14B 340B 5.32B 36.29B 14.39B 182B 13.52B 13.24B 576B
Net income 1.14B 1.04B 958M 865M 1.63B 108B 1.69B 11.51B 4.56B 57.58B 4.29B 4.2B 183B 1.41B 1.28B 1.18B 1.07B 2.01B 133B 2.08B 14.22B 5.64B 71.14B 5.3B 5.19B 226B
Net Debt -2.79B -2.53B -2.34B -2.11B -3.98B -263B -4.12B -28.11B -11.14B -141B -10.48B -10.25B -446B -3.89B -3.53B -3.26B -2.94B -5.55B -367B -5.74B -39.2B -15.54B -196B -14.61B -14.3B -622B
Projected Income Statement - Annual - United Therapeutics Corporation
Logo United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. It markets and sells commercial products, including Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI), Tyvaso (treprostinil) Inhalation Solution (Nebulized Tyvaso), Remodulin (treprostinil) Injection (Remodulin), Orenitram (treprostinil) Extended-Release Tablets (Orenitram), Unituxin (dinutuximab) Injection (Unituxin) and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and Nebulized Tyvaso to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). Unituxin, an infused monoclonal antibody for the treatment of high-risk neuroblastoma and for the treatment of neuroblastoma after high-dose chemotherapy. Adcirca, an oral immediate-release tablet form of the PDE-5 inhibitor tadalafil. Its THY-100 is in preclinical development for congenital athymia.
Employees
1,400
Date Price Change Volume
13/11/26 US$591.17 -0.36% 463,509
12/11/26 US$593.31 -0.39% 338,726
11/11/26 US$595.66 +1.20% 369,686
10/11/26 US$588.61 +1.06% 461,368
09/11/26 US$582.46 +3.64% 571,821
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - United Therapeutics Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
591.17USD
Average target price
687.14USD
Spread / Average Target
+16.23%
  1. Stock Market
  2. Stocks
  3. UTHR Stock